Clinical trial
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients
NCT05077332 is registered in ClinicalTrials.gov with Leidos Life Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients
- Lead sponsor
- Leidos Life Sciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 29, 2021
- Completion date
- November 10, 2025
- Enrollment
- 4 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
2019 novel coronavirus disease, 2019 novel coronavirus infection, 2019-ncov disease, 2019-ncov infection, coronavirus disease 2019, covid-19, covid-19 pandemic, covid-19 virus disease, covid-19 virus infection, covid19, sars-cov-2 acute respiratory disease, sars-cov-2 infection